HPV Archives

Gardasil approval delayed for use in women ages 27 – 45

Merck & Co., Inc. Receives Complete Response Letter from the Food and Drug Administration for Use of GARDASIL? in Women Ages 27 through 45 – Merck & Co., Inc. announced that the U.S. Food and Drug Administration has issued a second complete response letter regarding the supplemental biologics license application (sBLA) for the use of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] in women ages 27 though 45.

HPV vaccine’s hypersensitivity reactions are rare

Allergy and immunology consultant Liew Woei Kang and colleagues found that true hypersensitivity to the quadrivalent human papillomavirus vaccine was uncommon, and most girls in Australian schools tolerated subsequent doses. – Hypersensitivity reactions to the quadrivalent HPV vaccine (4vHPV, Gardasil) are uncommon and most schoolgirls can tolerate subsequent doses, finds the first evaluation of the quadrivalent HPV vaccine published on bmj.com.

Gardasil HPV vaccine prevented genital lesions in men

GARDASIL?, Merck’s Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study. – GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], the cervical cancer vaccine from Merck & Co., Inc., prevented 90 percent of external genital lesions caused by human papillomavirus (HPV) types 6, 11, 16 and 18 in a pivotal Phase III study in men aged 16 to 26.

Gardasil vaccine to prevent cervical cancer in India

Gardasil vaccine to prevent cervical cancer in India, launched by MSD Pharmaceuticals – the local affiliate of Merck. – MSD Pharmaceuticals India announced the launch of GARDASIL Vaccine, India’s first vaccine to help prevent Cervical Cancer caused by the HPV.

QIAGEN’s careHPV test provides more accurate screening

First published study of new HPV test – QIAGEN’s careHPV test for developing countries shows high accuracy in predicting cervical disease, cervical cancer. – A new HPV test developed by QIAGEN specifically for use in regions of the world with scarce resources is “substantially” more accurate in identifying women with cervical disease than the current methods (Pap testing and visual inspection) in these countries.

HPV vaccine Cervarix in UK’s immunisation programme

Jo’s Trust cervical cancer charity welcomes Department of Health’s announcement about HPV vaccine Cervarix. – The UK’s leading cervical cancer charity, Jo’s Trust, has welcomed the UK’s Department of Health’s announcement that the HPV vaccine, Cervarix will be used in the national immunisation programme for 12/13 year olds starting in September, 2008.

Persistent HPV infection raises cervical cancer risk

New research into the causes of cervical cancer appears to lend weight to the promise of a potential early detection method that could help prevent the disease. – Persistent infection with human papillomavirus (HPV) could be a useful clinical marker for increased risk of cervical cancer, the second most common cancer in women worldwide, revealed by researchers from the University of North Carolina at Chapel Hill.

Mothers less likely to vaccinate daughters against HPV

U.S. mothers report they are less likely to vaccinate daughters under age 13 against human papillomavirus virus (HPV), even though the vaccine is recommended for girls at age 11 and 12. – U.S. mothers report they are less likely to vaccinate daughters under age 13 against human papillomavirus virus (HPV), even though the vaccine is recommended for girls at age 11 and 12, it’s incumbent upon the healthcare community to work to improve mom’s acceptance of the vaccination for younger daughters, say researchers at Cincinnati Children’s Hospital Medical Center who conducted the study.

Alarming rates of STDs among teenage girls

A US study found that one in four teenage girls aged 14 to 19 has a sexually transmitted disease (STD). Nearly half the African-Americans in the study were infected by one of the diseases. – A US study found that one in four teenage girls aged 14 to 19 has a sexually transmitted disease (STD). Nearly half the African-Americans in the study were infected by one of the diseases. The survey, part of the National Health and Nutrition Examination Survey, did not ask about syphilis or gonorrhea, so it is likely the STD rates are actually higher.

Gardasil HPV vaccine reduces abnormal pap test results

In testing GARDASIL reduced abnormal Pap test results by 43 percent compared to women not given the vaccine, according new research. The findings show the approved anti-HPV agent appears to prevent the development of cell changes that lead to cervical disease. – A significant drop in abnormal Pap test results happened after girls and women were given Gardasil vaccine to prevent cervical cancer, according to a researcher at the University of Alabama at Birmingham (UAB).

Stress may increase cervical cancer risk

A woman’s daily stress can reduce her ability to fight off a common sexually transmitted disease and increase her risk of developing the cancer it can cause. – A woman’s daily stress can reduce her ability to fight off a common sexually transmitted disease and increase her risk of developing the cancer it can cause, according to a new study. No such association is seen, however, between past major life events, such as divorce or job loss, and the body’s response to the infection.

Tattooing improves DNA vaccine response

DNA-vaccination via tattooing induces stronger humoral and cellular immune responses than intramuscular delivery supported by molecular adjuvants. – Tattooing is a more effective way of delivering DNA vaccines; a tattoo can be more than just a fashion statement ? it has potential medical value, according to an article published in the online open access journal, Genetic Vaccines and Therapy.